Sulfur Containing Reactant Patents (Class 530/408)
-
Publication number: 20120164635Abstract: A compound of the following formula: wherein R1 is SO3H; R2 is chosen from carboxylic acid group and SO3H; and R3 is chosen from Cl, carboxylic acid group, amino, amino-carboxylic acid group, amido group, amino-amido group, and methods of use related to imaging.Type: ApplicationFiled: March 6, 2012Publication date: June 28, 2012Inventors: Wellington Pham, John C. Gore
-
Publication number: 20120156140Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.Type: ApplicationFiled: December 20, 2011Publication date: June 21, 2012Applicants: DYOMICS GMBH, PIERCE BIOTECHNOLOGY, INC.Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa Dworecki, Frank G. Lehmann
-
Publication number: 20120142606Abstract: The present invention is directed to peptides having affinity for tumor cells. The peptides are useful in pharmaceutical compositions in particular for the treatment of cancer. Further, the peptides are useful in diagnostic compositions, in particular for the diagnosis and imaging of cancer. The peptides according to the present invention are peptides selected from the group consisting of: Z1-KLAKLAKKLAKLAK-Z2-LTVXPWY-Z3, Z1-KLAKLAKKLAKLAK-Z2-LTVXP-Z3, Z1-KLAKLAKKLAKLAK-Z2-TVXPW-Z3, Z1-KLAKLAKKLAKLAK-Z2-VXPWY-Z3, Z1-KLAKLAKKLA KLAK-Z2-XPWY-Z3, Z1-KLAKLAKKLAKLAK-Z2-LTVXPW-Z3, di-, tri-, or multimers of the above sequences, wherein each Z1, Z2 and Z3 independently of one another represents any amino acid sequence of n amino acids, n varying from 0 to 50 and n being identical or different in Z1, Z2, and Z3, and wherein X represents any amino acid, whereby each of the amino acid residues in the above sequences may be independently in either L-form or D-form.Type: ApplicationFiled: April 1, 2009Publication date: June 7, 2012Inventors: Ingo Schmidt-Wolf, Davorka Messmer
-
Publication number: 20120115169Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: ApplicationFiled: November 9, 2010Publication date: May 10, 2012Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan
-
Publication number: 20120107857Abstract: Methods for detection of the activity of proteolytic enzymes, particularly isopeptidases, are disclosed.Type: ApplicationFiled: June 24, 2011Publication date: May 3, 2012Inventors: Dattananda Chelur, Michael Eddins, Craig Leach, Steven J. Orcutt, Raymond J. Peroutka, James Strickler, Yilin Yan, Kathryn Longenecker
-
Patent number: 8148500Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: September 21, 2010Date of Patent: April 3, 2012Assignee: Bolder BioTechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Publication number: 20120077284Abstract: Non-saturated or non-saturated and orientated binding surfaces for an affinity assay are provided, as are methods and compositions for their preparation. The non-saturated or non-saturated and orientated binding surfaces may further comprise paramagnetic microparticles. The methods include methods for making ligand::support coupler-based complexes by a process optionally employing a low input ratio of ligand to support coupler, by dilution, and by methods employing a dispersion and/or coating step using a block copolymer. Specific examples employing biotin-BSA and biotin-ovalbumin binding surfaces are provided, as well as strepavidin-coated microparticles and microparticles coated with capture moieties such as biotinylated immunoglobulins or fragments thereof. Other examples couple a ligand to the solid surface. Further provided are dispersed microparticles and methods for making them.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Inventors: Joshua C. Soldo, James L. Sackrison
-
Publication number: 20120064543Abstract: The present invention provides a method for detecting a substance in a biological sample, a carrier for using in the method, and a kit.Type: ApplicationFiled: March 2, 2010Publication date: March 15, 2012Applicants: VIRUS IKAGAKU KENKYUSHO INC., JAPAN TOBACCO INC.Inventors: Yoshimitsu Takakura, Naomi Oka, Kazuhiro Kondo
-
Publication number: 20120065330Abstract: The invention provides reagents and methods for conjugating a polymer specifically to the ?-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the ?-amine of a polypeptide having a cysteine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.Type: ApplicationFiled: October 26, 2011Publication date: March 15, 2012Applicant: Nektar TherapeuticsInventors: Michael J. Roberts, Zhihao Fang
-
Publication number: 20120065344Abstract: A modified compound that has at least one further functional group, in particular a bio- or macromolecule, comprising at least one x-fold (x?1) chemoselectively incorporated phosphoramidate group of general formula (I), NPO(OR1) (OR1?), and/or at least one x-fold (x?1) chemoselectively incorporated phosphonamide group of general formula (Ia), NPO(R1)(OR1?). R1 and R1? is selected from the group containing glycerol, polyglycerol, PEG polymers of the general empirical formula C2nH4n+2On+1 with n?1, Cn-alkyl chains with n?1; functionalized Cn-alkyl chains with n?1, aryls, heteroaryl, silyl, lipids, fluorophores, saccharides, peptides, crown ethers, or a linker, which links the aforementioned groups. R1 and R1? can be identical to or different from one another.Type: ApplicationFiled: March 9, 2010Publication date: March 15, 2012Applicant: FREIE UNIVERSITAET BERLINInventors: Christian Hackenberger, Giuseppe Del Signore, Remigiusz Serwa, Ina Wilkening, Robert Vallee
-
Publication number: 20120058478Abstract: The invention provides multimers of S. solfataricus ssDNA binding protein that bind single stranded DNA. The multimers are robust and stable reagents for use in PCR and other techniques for engineering DNA. The invention further provides methods for performing nucleic acid amplification and engineering using the multimers.Type: ApplicationFiled: November 8, 2010Publication date: March 8, 2012Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Cynthia A. Haseltine, Stephen C. Kowalczykowski
-
Publication number: 20120046737Abstract: Implantable biocompatible polymeric medical devices include a substrate with an acid or base-modified surface which is subsequently modified to include click reactive members.Type: ApplicationFiled: February 19, 2010Publication date: February 23, 2012Inventors: Nadya Belcheva, Ferass Abuzaina, Amin Elachchabi, Mbiya Kapiamba, Ahmad Robert Hadba
-
Publication number: 20120035346Abstract: Dyes and photoluminescent compounds based on polymethine dyes that contain at least one alkyl-phosphonate or substituted alkyl-phosphonate group, including the synthetic precursors, methods of synthesis, and applications thereof. Certain embodiments include heterocyclic ring systems and polymethine linkage are selected such that the resulting polymethine dye is a cyanine dye, a merocyanine dye, or a styryl dye.Type: ApplicationFiled: January 15, 2010Publication date: February 9, 2012Inventors: Ewald A. Terpetschnig, Leonid D. Patsenker, Larysa Markova, Iryna A. Fedyunyaeva, Olga S. Kolosova, Sergiy Starko, Anatoliy Tatarets
-
Patent number: 8092811Abstract: The present invention relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present invention also provides peptides interacting with fibronectin, laminin and the complement system.Type: GrantFiled: August 8, 2006Date of Patent: January 10, 2012Assignee: Arne Forsgren ABInventors: Arne Forsgren, Kristian Riesbeck
-
Publication number: 20120004397Abstract: The present invention provides dye compounds optimally excited at about 400 nm and have a Stokes shift of at least about 80 nm. These dyes find use in detection of analyte in a sample and the preparation of dye-conjugates.Type: ApplicationFiled: May 31, 2011Publication date: January 5, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Gayle Buller, Jixiang Liu, Stephen T. Yue, Jolene Bradford
-
Publication number: 20120003260Abstract: One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof.Type: ApplicationFiled: May 17, 2011Publication date: January 5, 2012Applicant: Massachusetts Institute of TechnologyInventors: Peter H. Seeberger, Michael C. Hewitt, Daniel Snyder
-
Publication number: 20110313129Abstract: Provided herein are heptamethine cyanine dyes having a large Stokes shift, and the salts and conjugates thereof. Also provided are methods of using and making such large Stokes shift dyes as fluorescence resonance energy transfer (FRET) acceptors or donors.Type: ApplicationFiled: February 10, 2010Publication date: December 22, 2011Applicant: Life Technologies CorporationInventors: Yi-Zhen Hu, Hee Chol Kang
-
Publication number: 20110311505Abstract: This invention is related to preparation of photosensitive ruthenium based aminoacid monomers and oligomers, aminoacid monomer-protein cross-linking using photo sensitat ion and conjugation on micro and nano-structures by ruthenium-chelate based monomers. Its vast range biotechnolgy applications of multifunctional, biocompatible, stabilE and specific micro and nanobio-conjugates, which will stand-alone or simultaneously enable (i) both purification and determination, (ii) both targeting and imaging and theranostics and (iii) catalysis and determination. The construction and method of preparation is applicable to silica materials, superparamagnetic particles, QDs, CNTs, Ag/Au nanoparticles and Au surfaces and polymeric materials. The photosensitive aminoacid monomer linkers can react via chemically and biocompatible to a lot of different micro and nano-surface and then to the protein when they act as a single-step cross-linking reaction using irradiation.Type: ApplicationFiled: December 11, 2009Publication date: December 22, 2011Inventors: Arzu Ersoz, Deniz Hur, Filiz Yilmaz, Adil Denizli, Ayca Atilir Ozcan, Sibel Emir Diltemiz, Suzan Yazar, Ozlem Bicen, Sibel Buyuktiryaki, Rustem Kecili, Guner Saka, Tugba Findik
-
Publication number: 20110300160Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation.Type: ApplicationFiled: April 15, 2011Publication date: December 8, 2011Inventors: Joshua Rabbani, James J. Donegan
-
Publication number: 20110294869Abstract: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.Type: ApplicationFiled: September 23, 2009Publication date: December 1, 2011Applicant: Traversa Therapeutics, Inc.Inventor: Scott G. Petersen
-
Publication number: 20110288280Abstract: There has been a need for coelenteramide analogs or the like that produce fluorescent proteins which exhibit different fluorescent characteristics from those of the existing fluorescent proteins. Disclosed is a compound represented by general formula (1) (wherein R1 represents a substituted or unsubstituted aryl, a substituted or unsubstituted arylalkyl, a straight or branched alkyl which may optionally be substituted with an alicyclic group, an alicyclic group or a heterocyclic group; R2 represents hydrogen or —(SO2)R4; R3 represents hydrogen, hydroxyl, methoxy or acetoxy; R4 represents a substituted or unsubstituted aryl, a substituted or unsubstituted arylalkyl or a straight or branched alkyl which may optionally be substituted with an alicyclic group; and X1 represents —C(?S)— or —SO2—).Type: ApplicationFiled: February 8, 2010Publication date: November 24, 2011Applicants: TOKYO INSTITUTE OF TECHNOLOGY, JNC CORPORATIONInventors: Takamitsu Hosoya, Kohei Oka, Satoshi Inouye
-
Patent number: 8058409Abstract: A means for pre-treatment in glycomic analysis of a glycoprotein is provided by the present invention. A salt of the general formula (I): wherein Z, X, R1, R2, M, m and n are the same as described in DESCRIPTION, is useful as a protein solubilizer, and an oligosaccharide is efficiently released from a sample if reductive alkylation and/or digestion by a proteinase are carried out under the presence of the said solubilizer at the first step in the glycomic analysis of glycoprotein derived from a living body.Type: GrantFiled: June 29, 2007Date of Patent: November 15, 2011Assignees: National University Corporation Hokkaido University, Shionogi & Co., Ltd.Inventors: Shin-Ichiro Nishimura, Yasuro Shinohara, Yoshiaki Miura, Jun-ichi Furukawa, Yoko Kita, Akio Takimoto, Mika Nakano
-
Publication number: 20110269943Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.Type: ApplicationFiled: June 28, 2010Publication date: November 3, 2011Applicants: University of Washington, Poniard Pharmaceuticals, Inc.Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
-
Publication number: 20110263975Abstract: The present invention relates to quenched fluorescent probes which arc activated by biochemical processes. The probes are designed such that intramolecular quenching occurs in the unactivated probe, but that the quencher moieties are cleaved from the probe under defined conditions rendering the probe fluorescent. Also disclosed are optical imaging agents suitable for in vivo imaging comprising the probes, as well as pharmaceutical compositions and kits, as well as in vivo imaging methods.Type: ApplicationFiled: December 22, 2009Publication date: October 27, 2011Applicant: GE HEALTHCARE ASInventor: Helge Tolleshaug
-
Publication number: 20110262366Abstract: The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.Type: ApplicationFiled: December 15, 2010Publication date: October 27, 2011Applicant: BRACCO INTERNATIONAL B.V.Inventors: Mathew A. Von Wronski, Edmund R. Marinelli, Adrian D. Nunn, Radhakrishna K. Pillai, Kondareddiar Ramalingam, Michael F. Tweedle, Karen E. Linder, Palaniappa Nanjappan, Natarajan Raju, Feng Yan, Michel Schneider
-
Publication number: 20110230649Abstract: Disclosed embodiments relate to antibodies that recognize redox modulated proteins such as glutathionylated actin. Embodiments relate to a reagent for the immunoassay of glutathionylated actin. Disclosed embodiments also relate to diagnosis of and therapies for the treatment of diseases related to impaired deglutathionylation of peptides. Additionally, disclosed embodiments relate to pharmaceutical compositions containing antibodies which recognize redox modulated proteins and kits for the detection or treatment of diseases related to redox modulated proteins which include antibodies that recognize redox modulated proteins.Type: ApplicationFiled: March 18, 2011Publication date: September 22, 2011Applicant: NITAN BIOTECH LLCInventor: Srikanth Vedamoorthy
-
Publication number: 20110223151Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.Type: ApplicationFiled: August 6, 2009Publication date: September 15, 2011Applicant: Novo Nordisk Health Care AGInventors: Carsten Behrens, Patrick William Garibay, Soren Østergaard, Henrik Sune Andersen, Johansen Nils Langeland, Peschke Bernd, Bak Sonja
-
Publication number: 20110223422Abstract: Hydroxyl polymer-containing compositions, especially hydroxyl polymer-containing compositions that can be processed into polymeric structures, especially polymeric structures in the form of fibers are provided.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Inventors: Paul Arlen Forshey, Gregory Charles Gordon, Larry Neil Mackey, Mark Ryan Richards
-
Publication number: 20110217732Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: ApplicationFiled: October 21, 2010Publication date: September 8, 2011Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: LINDA HSIEH-WILSON, NELLY KHIDEKEL, HWAN-CHING TAI, SABINE ARNDT
-
Publication number: 20110201781Abstract: A method of use of a cysteine labeling system includes: providing a 2-cyano benzothial core with a covalently-linked biomolecule X in a reaction environment; and reacting the 2-cyano benzothial core to an N-terminal cystenine.Type: ApplicationFiled: September 16, 2009Publication date: August 18, 2011Inventors: Jianghong Rao, Hongjun Ren
-
Publication number: 20110184147Abstract: The present invention provides a substrate of TGase represented by (fluorescent group)-(linker)-(a portion containing a Gln residue capable of recognition by transglutaminase (TGase))-R, wherein the fluorescent group is fluorescein isothiocyanate (FITC), Texas Red (TE) or dansyl (Dns) or a group derived therefrom; the linker is a group represented by —NH—(CH2)n—CO— (n is an integer of 1 to 6); the portion containing a Gln residue capable of recognition by TGase is a group derived from a peptide selected from among QG and the like; and R is a hydroxyl group, or biotin, nucleic acid, azide, alkyne, maleimide or cyclopentadiene, or a group derived therefrom.Type: ApplicationFiled: July 3, 2009Publication date: July 28, 2011Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Noriho Kamiya, Masahiro Goto, Hiroki Abe
-
Publication number: 20110144304Abstract: The invention relates to methods for selectively converting a cysteine residue in a peptide or protein to the dehydroalanine (Dha) residue. The method also works on selenocysteine and substituted cysteine and selenocysteine residues, resulting in the Dha residue which may be converted to any natural or unnatural amino acid residue desired without the alteration of the remainder of the peptide or protein. The invention also allows ligation of a desired peptide at any point rather than at a point where there should be a naturally occurring cysteine, thereby allowing native chemical ligation to be used in the synthesis of peptides that do not contain cysteine. The methodology allows for the synthesis of very large peptides.Type: ApplicationFiled: January 23, 2009Publication date: June 16, 2011Inventors: Goncalo Bernardes, Justin Chalker, Benjamin Davis
-
Publication number: 20110142762Abstract: This invention relates to the delivery of agents to the body. One particular class of such agents are contrast agents useful in medical imaging techniques. The agents may be metals useful as contrast agents in magnetic resonance imaging (MRI), or in nuclear imaging, including positron emission tomography (PET), or as therapeutic agents in radiotherapy. The agents may alternatively be contrast agents useful in X-ray imaging. The invention also relates to methods by which agents for delivery to the body can be coupled to carriers and to targeting moieties effective to direct the agent to a specific locus within the body.Type: ApplicationFiled: January 19, 2011Publication date: June 16, 2011Applicants: Novozymes Biopharma DK A/S, Upperton LimitedInventor: John Rodney Woodrow
-
Patent number: 7947672Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<?>, COS<?>, SO3<?>, PO3<2?>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.Type: GrantFiled: November 17, 2003Date of Patent: May 24, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Avigdor Scherz, Alexander Brandis, Ohad Mazor, Yoram Salomon, Hugo Scheer
-
Publication number: 20110111422Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.Type: ApplicationFiled: September 1, 2010Publication date: May 12, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Kurt VOGEL, Rhonda Newman, Steven Riddle
-
Publication number: 20110092678Abstract: The invention relates to labelling agents containing a compound with a labelled molecule and a vinyl sulphone group. The invention also relates to the compounds, the method for obtaining them and the uses thereof in the marking of biomolecules and, more specifically, proteins.Type: ApplicationFiled: February 19, 2009Publication date: April 21, 2011Inventors: Francisco Santoyo González, Fernando Hernández Mateo, Francisco Javier Lopez Jaramillo, Mariano Ortega Muñoz
-
Patent number: 7928205Abstract: The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.Type: GrantFiled: October 21, 2005Date of Patent: April 19, 2011Assignee: Amgen Inc.Inventors: Thomas M. Dillon, Douglas Rehder, Pavel Bondarenko, Margaret Ricci, Himanshu S. Gadgil, Douglas D. Banks, Joe Zhou, Yuefeng Lu, Andrew Goetze, Yuling Zhang
-
Publication number: 20110085939Abstract: Engineered proteins are used in the assembly of two-dimensional and three-dimensional nanostructure assemblies, based on systematic design and production of protein node structures that can be interconnected, for example, with streptavidin or streptavidin-incorporating struts to produce structures with defined dimensions and geometry. Nanostructure assemblies having utility as functional devices or as resists for the patterning of substrates have architectures including polygons, polyhedra, two-dimensional lattices, and three-dimensional lattices.Type: ApplicationFiled: September 28, 2010Publication date: April 14, 2011Applicant: IMIPLEX LLCInventors: F. Raymond Salemme, Patricia C. Weber, Mark A. Rould
-
Publication number: 20110082282Abstract: Processes using Allium tissue homogenates and extracts in a simple and cost-effective manner to maximize the yields and recovery of thiosulfinates from Allium tissues and related organisms possessing alliinase, LF synthase and/or S-alk(en)yl-L-cysteine sulfoxides are disclosed.Type: ApplicationFiled: October 5, 2010Publication date: April 7, 2011Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Kirk L. Parkin, Guodong Zhang
-
Publication number: 20110077265Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3?, R4, R4? and R5, are as described herein.Type: ApplicationFiled: April 29, 2008Publication date: March 31, 2011Applicant: Genentech, Inc.Inventors: John A. Flygare, Frederick Cohen, Kurt Deshayes, Michael F. T. Koehler, Lewis J. Gazzard, Lan Wang, Chudi Ndubaku
-
Patent number: 7914787Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: May 29, 2009Date of Patent: March 29, 2011Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, William J. McBride
-
Publication number: 20110070656Abstract: A fluorescent protein (bFP) having chemiluminescence activity is a complex composed of the apoprotein of a calcium-binding photoprotein, coelenteramid or an analog thereof, and calcium ions or divalent or trivalent ions that can be substituted for the calcium ions. In the complex, the ratio of the number of molecules of the apoprotein to that of the coelenteramid is 1:1 and the ratio of the number of molecules of the apoprotein to that of the divalent or trivalent ions is 1:1 to 1:4. The fluorescent protein is used as a marker because it catalyzes luminescence of coelenterazine and has fluorescence capability. Removal of calcium ions etc. from this fluorescent protein (bFP) having luminescence activity provides a novel fluorescent protein (gFP). Mixing this gFP with the coelenterazine provides a calcium-binding photoprotein, which emit light instantaneously, enabling use as a marker.Type: ApplicationFiled: August 12, 2004Publication date: March 24, 2011Inventor: Satoshi Inouye
-
Publication number: 20110065196Abstract: The present invention provides a method of forming an ion of formula (I) comprising the steps of: (i) reacting a compound of the formula (IIa); with a biopolymer, BP, having at least one group capable of reacting with M to form a covalent linkage, to provide a biopolymer derivative of the formula (IIIa); and (ii) cleaving the C—X bond between X and the ?-carbon atom of the derivative of formula (IIIa) to form the ion of formula (I); where: (IV) is a carbon atom bearing a single positive charge or a single negative charge; and X is a group comprising a thioether sulphur atom bound directly to the ?-carbon which is capable of being cleaved from the ?-carbon atom to form an ion of formula (I). The biopolymer derivatives of the invention have enhanced ionisability with respect to free biopolymer (BP) enabling improved analysis of the biopolymer using mass spectrometry.Type: ApplicationFiled: June 16, 2006Publication date: March 17, 2011Inventors: Mikhail Shchepinov, Pablo Bernad
-
Publication number: 20110059953Abstract: Compounds of formula (I): wherein X is selected from CRX and N; RN1 is selected from H and C1-4 alkyl, which may be substituted by SH or halo; RG1 is selected from H and SH; RC2 is selected from H and optionally substituted C1-7 alkyl; RC3 is selected from H and optionally substituted C1-7 alkyl; Rx is selected from H, OH and NH2; RC4 is selected from: (i) an optionally substituted C3-12 N-containing heterocyclyl; (ii) C(?O)NRN5RN6, where RN5 and RN6 are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C3-20 heterocyclyl and optionally substituted C5-20 aryl or RN5 and RN6 and the nitrogen atom to which they are attached form an optionally substituted N-containing C5-7 heterocyclyl group; (iii) C(?O)ORO1, where RO1 is selected from H, optionally substituted C1-7 alkyl, optionally substituted C3-20 heterocyclyl and optionally substituted C5-20 aryl; (iv) C(?O)NHNHSO2RS1, where RS1 is selected from H, optionally substituted C1-7 alkyl, optionally substituted C3-20 heterocType: ApplicationFiled: May 7, 2009Publication date: March 10, 2011Inventors: Frank Boeckler, Andreas Joerger, Alan Fersht
-
Publication number: 20110046000Abstract: The presently disclosed subject matter provides dyes having an improved photostability, biosensors comprising such dyes, and methods of use thereof, including methods for detecting target molecules in a sample under test and for live-cell imaging. The dyes can include a binding member, including a biomolecule or fragments thereof, which can interact with target molecules of interest and can be specific to a given conformational state or covalent modification, e.g., phosphorylation, of the target molecule. The presently disclosed dyes can be used for detecting changes in the binding, conformational change, or posttranslational modification of the target molecule.Type: ApplicationFiled: June 20, 2008Publication date: February 24, 2011Inventors: Klaus Hahn, Alexei Toutchkine
-
Patent number: 7893210Abstract: A method for renaturation of proteins comprising adding to a solution of denatured, chemically modified or reduced proteins a refolding buffer containing a primary, secondary or tertiary amine. Said method has been applied, for example, to interleukin-4 and bovine pancreatic trypsin inhibitor (BPTI), which were previously (i) solubilized in the presence of guanidinium hydrochloride as chaotronic agent, and (ii) subjected to sulfitolysis.Type: GrantFiled: November 12, 2002Date of Patent: February 22, 2011Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Jörg Peters, Torsten Minuth
-
Publication number: 20110034678Abstract: The present invention provides large-scale methods for renaturation of proteins comprising adding a solution of denatured, chemically modified or reduced proteins to a refolding buffer containing sulfate derived from H2SO4 and/or MgSO4 in the presence of guanidine. The present invention further provides methods of isolating a refolded protein at a concentration of about 0.4 to 3.0 gm/L by using a hydrophobic interaction chromatography (HIC) column.Type: ApplicationFiled: March 12, 2010Publication date: February 10, 2011Applicant: AEROVANCE, INC.Inventors: Wayne Froland, Katherine Delaria, David Boisvert, Robert Kuhn
-
Publication number: 20110014216Abstract: The invention relates to coenzyme A (CoA) type compounds carrying one or more drug entities and optionally a label detectable by a fluorescence detector, magnetic resonance imaging (MRI), positron emission tomography (PET) or scintigraphy, and/or a functional group which can be transformed into a drug or a detectable label. The invention further relates to a molecular shuttle which is a fusion protein comprising a proteinaceous binding entity directed to a target and an acyl carrier protein (ACP) or a fragment thereof, and carrying one or more drug entities. The proteinaceous binding entity is designed to bind to a target structure in vitro or in vivo, for example a cellular receptor.Type: ApplicationFiled: October 2, 2008Publication date: January 20, 2011Applicant: COVALYS BIOSCIENCES AGInventors: Andreas Brecht, Florent Beaufils
-
Publication number: 20110008811Abstract: A resin connected by amide bond to pyridyl sulfide or methylthiosulfonate can be conjugated to a post traditionally modified protein/peptide to allow determination of presence and kind and optionally location of cysteine modification(s).Type: ApplicationFiled: December 10, 2008Publication date: January 13, 2011Applicant: DUKE UNIVERSITYInventors: Jonathan Stamler, Michael Forrester, Matthew Foster
-
Publication number: 20110003362Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.Type: ApplicationFiled: July 12, 2010Publication date: January 6, 2011Inventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang, Xiang Guobing